Exelixis Inc. (EXEL)

Cabozantinib revenue grew 10%, while zanzalintinib advances toward FDA decision in December.

In early August 2026, Exelixis reported second-quarter results showing revenue of US$628.69 million and net income of US$212.05 million, with earnings per share increasing versus the prior year, but s...

Exelixis stock toppled Thursday on a mixed second-quarter report, as sales of its bread-and-butter cancer drug lagged expectations.

Exelixis beats EPS estimates but misses on revenues; cuts 2026 outlook as a slower-than-expected NET launch weighs on expectations.

Exelixis Inc (EXEL) reports robust Q2 2026 results with $629M in revenues, while navigating slower NET adoption and advancing its zanzalintinib pipeline toward key regulatory milestones.